Literature DB >> 26785963

Cost analysis of nucleic acid amplification for diagnosing pulmonary tuberculosis, within the context of the Brazilian Unified Health Care System.

Márcia Pinto1, Aline Piovezan Entringer2, Ricardo Steffen2, Anete Trajman1.   

Abstract

We estimated the costs of a molecular test for Mycobacterium tuberculosis and resistance to rifampin (Xpert MTB/RIF) and of smear microscopy, within the Brazilian Sistema Único de Saúde (SUS, Unified Health Care System). In SUS laboratories in the cities of Rio de Janeiro and Manaus, we performed activity-based costing and micro-costing. The mean unit costs for Xpert MTB/RIF and smear microscopy were R$35.57 and R$14.16, respectively. The major cost drivers for Xpert MTB/RIF and smear microscopy were consumables/reagents and staff, respectively. These results might facilitate future cost-effectiveness studies and inform the decision-making process regarding the expansion of Xpert MTB/RIF use in Brazil.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26785963      PMCID： PMC4722795          DOI： 10.1590/S1806-37562015000004524

Source DB:  PubMed          Journal:  J Bras Pneumol        ISSN： 1806-3713            Impact factor:   2.624


  8 in total

1.  Cost-effectiveness of Xpert® MTB/RIF for diagnosing pulmonary tuberculosis in the United States.

Authors:  H W Choi; K Miele; D Dowdy; M Shah
Journal:  Int J Tuberc Lung Dis       Date:  2013-10       Impact factor: 2.373

2.  [National guidelines for research involving human tissue repositories and biobanks].

Authors: 
Journal:  Rev Saude Publica       Date:  2009-10       Impact factor: 2.106

Review 3.  Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Karen R Steingart; Hojoon Sohn; Ian Schiller; Lorie A Kloda; Catharina C Boehme; Madhukar Pai; Nandini Dendukuri
Journal:  Cochrane Database Syst Rev       Date:  2013-01-31

4.  Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis.

Authors:  Anna Vassall; Sanne van Kampen; Hojoon Sohn; Joy S Michael; K R John; Saskia den Boon; J Lucian Davis; Andrew Whitelaw; Mark P Nicol; Maria Tarcela Gler; Anar Khaliqov; Carlos Zamudio; Mark D Perkins; Catharina C Boehme; Frank Cobelens
Journal:  PLoS Med       Date:  2011-11-08       Impact factor: 11.069

5.  The impact and cost of scaling up GeneXpert MTB/RIF in South Africa.

Authors:  Gesine Meyer-Rath; Kathryn Schnippel; Lawrence Long; William MacLeod; Ian Sanne; Wendy Stevens; Sagie Pillay; Yogan Pillay; Sydney Rosen
Journal:  PLoS One       Date:  2012-05-31       Impact factor: 3.240

6.  Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation.

Authors:  Nicolas A Menzies; Ted Cohen; Hsien-Ho Lin; Megan Murray; Joshua A Salomon
Journal:  PLoS Med       Date:  2012-11-20       Impact factor: 11.069

7.  Comparison of laboratory costs of rapid molecular tests and conventional diagnostics for detection of tuberculosis and drug-resistant tuberculosis in South Africa.

Authors:  Maunank Shah; Violet Chihota; Gerrit Coetzee; Gavin Churchyard; Susan E Dorman
Journal:  BMC Infect Dis       Date:  2013-07-29       Impact factor: 3.090

8.  Impact of replacing smear microscopy with Xpert MTB/RIF for diagnosing tuberculosis in Brazil: a stepped-wedge cluster-randomized trial.

Authors:  Betina Durovni; Valeria Saraceni; Susan van den Hof; Anete Trajman; Marcelo Cordeiro-Santos; Solange Cavalcante; Alexandre Menezes; Frank Cobelens
Journal:  PLoS Med       Date:  2014-12-09       Impact factor: 11.069
  8 in total
  9 in total

1.  Accuracy of a rapid molecular test for tuberculosis in sputum samples, bronchoalveolar lavage fluid, and tracheal aspirate obtained from patients with suspected pulmonary tuberculosis at a tertiary referral hospital.

Authors:  Tatiane Maria da Silva; Valéria Martins Soares; Mariana Gontijo Ramos; Adriana Dos Santos
Journal:  J Bras Pneumol       Date:  2019-03-11       Impact factor: 2.624

2.  The need for a balance between highly prevalent diseases and neglected diseases.

Authors:  Rogério Souza
Journal:  J Bras Pneumol       Date:  2018 Nov-Dec       Impact factor: 2.624

3.  Current use and acceptability of novel diagnostic tests for active tuberculosis: a worldwide survey.

Authors:  Massimo Amicosante; Lia D'Ambrosio; Marcela Munoz; Fernanda Carvalho de Queiroz Mello; Marc Tebruegge; Novel Njweipi Chegou; Fouad Seghrouchni; Rosella Centis; Delia Goletti; Graham Bothamley; Giovanni Battista Migliori
Journal:  J Bras Pneumol       Date:  2017 Sep-Oct       Impact factor: 2.624

4.  Rapid molecular test for tuberculosis: impact of its routine use at a referral hospital.

Authors:  Marilda Casela; Silvânia Maria Andrade Cerqueira; Thais de Oliveira Casela; Mariana Araújo Pereira; Samanta Queiroz Dos Santos; Franco Andres Del Pozo; Songeli Menezes Freire; Eliana Dias Matos
Journal:  J Bras Pneumol       Date:  2018-04       Impact factor: 2.624

5.  Performance of diagnostic tests for pulmonary tuberculosis in indigenous populations in Brazil: the contribution of Rapid Molecular Testing.

Authors:  Jocieli Malacarne; Alexsandro Santos Heirich; Eunice Atsuko Totumi Cunha; Ida Viktoria Kolte; Reinaldo Souza-Santos; Paulo Cesar Basta
Journal:  J Bras Pneumol       Date:  2019-04-18       Impact factor: 2.624

6.  Cost-Utility Analysis of Wide-Field Imaging as an Auxiliary Technology for Retinopathy of Prematurity Care in Brazil.

Authors:  Luiza M Neves; Lorena M Haefeli; Andrea A Zin; Ricardo E Steffen; Zilton F M Vasconcelos; Márcia Pinto
Journal:  Front Pediatr       Date:  2021-12-16       Impact factor: 3.418

7.  Genotype®MTBDRplus and Xpert®MTB/RIF in the diagnosis of tuberculosis and resistant tuberculosis: cost analysis in a tertiary referral hospital.

Authors:  Valéria Martins Soares; Isabela Neves de Almeida; Maria Cláudia Vater; Suely Alves; Lida Jouca de Assis Figueredo; Luciene Scherer; Afrânio Lineu Kritski; Wânia da Silva Carvalho; Silvana Spindola de Miranda
Journal:  Rev Soc Bras Med Trop       Date:  2020-02-07       Impact factor: 1.581

8.  Cost-effectiveness of a Pharmacogenomic Test for Stratified Isoniazid Dosing in Treatment of Active Tuberculosis.

Authors:  Neil E Rens; Carin A Uyl-de Groot; Jeremy D Goldhaber-Fiebert; Julio Croda; Jason R Andrews
Journal:  Clin Infect Dis       Date:  2020-12-15       Impact factor: 9.079

9.  Costs and cost-effectiveness of Gene Xpert compared to smear microscopy for the diagnosis of pulmonary tuberculosis using real-world data from Arsi zone, Ethiopia.

Authors:  Abdene Weya Kaso; Alemayehu Hailu
Journal:  PLoS One       Date:  2021-10-25       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.